FDA Approves First Gene Therapy for Adults With Hemophilia B
MONDAY, Nov. 28, 2022 (HealthDay News) — The U.S. Food and Drug Administration has approved Hemgenix (etranacogene dezaparvovec) for the treatment of hemophilia B in adults.Hemgenix, an adeno-associated virus vector-based gene therapy, is administere…
Learn MoreA Gene Therapy for Hemophilia That Costs $3.5 Million Gets FDA Approval
WEDNESDAY, Nov. 23, 2022 (HealthDay News) — People with one form of the genetic blood disorder hemophilia now have a one-time treatment with a $3.5 million price tag.The U.S. Food and Drug Administration approved the new gene therapy Hemgenix on Nov….
Learn MoreLa terapia genética logra avances contra una forma de hemofilia
VIERNES, 22 de julio de 2022 (HealthDay News) — Las personas con hemofilia B podrían experimentar una reducción dramática en su riesgo de sangrado con tan solo una inyección de una terapia genética experimental, informa un nuevo estudio. La hemofilia…
Learn MoreGene Therapy Makes Inroads Against a Form of Hemophilia
FRIDAY, July 22, 2022 (HealthDay News) — People with hemophilia B could find their bleeding risk dramatically reduced with just one injection of an experimental gene therapy, a new study reports.Hemophilia B is a rare and inherited genetic disorder i…
Learn More